Genentech Avastin Labeling Will Reflect New Data On Thromboembolic Events

Genentech is in discussions with FDA on revisingAvastin labeling to reflect an increased risk of thromboembolic events

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet